Table 4.
Outcomes of newly diagnosed MM patients included in the Spanish Myeloma trials (GEM05MAS65, GEM05MENOS65, GEM2010, GEM2012) by cytogenetic abnormalities.
| Frec, % (No. of patients studied) | Median PFS (m) | 3‐yr PFS (%) | HR (95% CI) | p‐value | Median OS (m) | 3‐yr OS (%) | HR (95% CI) | p‐value | |
|---|---|---|---|---|---|---|---|---|---|
| t(4;14) | 12.2 (1165) | 27.7 | 44.3 | 1.5 (1.2–1.8) | <0.001 | 49.3 | 61.0 | 2.0 (1.5–2.5) | <0.001 |
| Non t(4;14) | 45.3 | 56.7 | NR | 80.2 | |||||
| t(14;16) | 2.7 (1150) | 27.5 | 45.2 | 1.2 (0.8–1.9) | NS | NR | 58.1 | 1.4 (0.8–2.4) | NS |
| Non t(14;16) | 43.6 | 55.3 | NR | 78.4 | |||||
| del17p | 7.7 (1157) | 23.9 | 29.5 | 1.9 (1.5–2.4) | <0.001 | 36.9 | 50.9 | 2.5 (1.9–3.3) | <0.001 |
| Non del17p | 46.0 | 57.5 | NR | 80.4 | |||||
| Gain (1q) | 40.1 (906) | 36.5 | 50.1 | 1.4 (1.2–1.7) | <0.001 | 80.6 | 73.9 | 1.5 (1.2–1.9) | <0.001 |
| Non gain (1q) | 53.2 | 62.2 | NR | 83.4 | |||||
| del(1p) | 5.2 (902) | 41.1 | 51.0 | 0.7 (0.5–0.97) | 0.04 | NR | 80.6 | 0.7 (0.4–1.1) | NS |
| Non del(1p) | 48 | 57.0 | NR | 67.6 |
Abbreviations: CI, confidence interval; frec, frequency; HR, hazard ratio; MM, multiple myeloma; mo, months; No., number of patients; NR, not reached; NS, not statistically significant; OS, overall survival; PFS, progression‐free survival; yr, years.